Codiak BioSciences, Inc. (CDAK)
Price:
0.06 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
NEWS
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
investorplace.com
2023-03-27 12:17:56Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences started the marketing process before entering into Chapter 11.
Codiak BioSciences files for bankruptcy, looks to sell off assets
marketwatch.com
2023-03-27 07:26:00Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” the Massachusetts-based biopharmaceutical company said in a statement.
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2022-11-03 18:48:16Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
globenewswire.com
2022-10-05 08:00:00– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-04 18:48:32Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
benzinga.com
2022-06-30 09:52:02Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-05 19:34:24Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com
2022-03-29 11:17:14After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
247wallst.com
2022-03-12 06:10:37While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2022-03-10 18:48:25Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Stock Jumps 18.2%: Will It Continue to Soar?
zacks.com
2022-02-01 03:54:03Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
globenewswire.com
2022-01-06 09:00:00CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.
Codiak BioSciences (CDAK) Stock: Why The Price Jumped Today
pulse2.com
2021-12-02 15:01:03The stock price of Codiak BioSciences Inc (NASDAQ: CDAK) increased by over 8% during intraday trading today. This is why it happened.
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
globenewswire.com
2021-12-01 16:05:00CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. Details are as follows:
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
benzinga.com
2021-11-16 10:47:42Codiak BioSciences Inc (NASDAQ: CDAK) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exosome therapeutic candidate.
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Misses Revenue Estimates
zacks.com
2021-11-04 18:19:04Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of -2.11% and -59.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
No data to display
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
investorplace.com
2023-03-27 12:17:56Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences started the marketing process before entering into Chapter 11.
Codiak BioSciences files for bankruptcy, looks to sell off assets
marketwatch.com
2023-03-27 07:26:00Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” the Massachusetts-based biopharmaceutical company said in a statement.
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2022-11-03 18:48:16Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
globenewswire.com
2022-10-05 08:00:00– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-04 18:48:32Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
benzinga.com
2022-06-30 09:52:02Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-05 19:34:24Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com
2022-03-29 11:17:14After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
247wallst.com
2022-03-12 06:10:37While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2022-03-10 18:48:25Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Stock Jumps 18.2%: Will It Continue to Soar?
zacks.com
2022-02-01 03:54:03Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
globenewswire.com
2022-01-06 09:00:00CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.
Codiak BioSciences (CDAK) Stock: Why The Price Jumped Today
pulse2.com
2021-12-02 15:01:03The stock price of Codiak BioSciences Inc (NASDAQ: CDAK) increased by over 8% during intraday trading today. This is why it happened.
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
globenewswire.com
2021-12-01 16:05:00CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. Details are as follows:
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
benzinga.com
2021-11-16 10:47:42Codiak BioSciences Inc (NASDAQ: CDAK) announced initial data for exoSTING currently in a Phase 1/2 trial as a single agent for the treatment of multiple solid tumors. ExoSTING is an engineered exosome therapeutic candidate.
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Misses Revenue Estimates
zacks.com
2021-11-04 18:19:04Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of -2.11% and -59.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?